Suppr超能文献

COVID-19 治疗中的液体限制管理:一项单中心观察性研究。

Fluid restriction management in the treatment of COVID-19: a single-center observational study.

机构信息

Department of Intensive Care, Chiba Emergency Medical Center, 3-32-1, Isobe, Mihama, Chiba, Chiba, 261-0012, Japan.

Department of Anesthesiology, Chiba Emergency Medical Center, Chiba, Chiba, Japan.

出版信息

Sci Rep. 2022 Oct 15;12(1):17339. doi: 10.1038/s41598-022-22389-5.

Abstract

The relationship between fluid management and the severity of illness, duration of treatment, and outcome of coronavirus disease 2019 (COVID-19) is not fully understood. This study aimed to evaluate whether weight change during hospitalization was associated with COVID-19 severity, length of hospital stay, and route of admission. In this study, we assessed the effectiveness of fluid restriction management in patients with severe COVID-19. COVID-19 patients admitted to our hospital between July 2020 and October 2021 were analyzed. Patients were treated with standard drug therapy based on the Japanese guidelines and respiratory support according to the severity of the disease. Early enteral nutrition, defecation management, and anticoagulation therapy were also administered. Fluid restriction management was performed using furosemide and continuous renal replacement therapy as needed unless hemodynamic instability or hyperlactatemia was present. Patient background, route of admission (ambulance, A; transfer, T), weight at admission and discharge, the severity of illness (oxygen therapy, G1; mechanical ventilation, G2; extracorporeal membrane oxygenation, G3), in-hospital mortality, and length of hospital stay were analyzed. There were 116 subjects: G1 (n = 48), G2 (n = 43), and G3 (n = 25), with ages (median [IQR]) of 58 (47-70), 65 (53-71.5), 56 (51-62) years, 40 (83.3%), 31 (72.1%), and 19 (76.0%) males, respectively. Hospital stays were 4.5 (2-7), 10 (7-16), and 18 (15-26) days, and the in-hospital mortality rates were 0 (0%), 7 (16.3%), and 8 (32%), respectively. Body mass index on admission was 26 (23.1-30.2), 27.1 (22.7-31.1), and 31.5 (27.1-33.1) kg/m, and weight loss during admission was 1.1 (0-2.9), 4.6 (2.3-5.7), 9.2 (5.6-10.5) kg (P < 0.001, Jonckheere-Terpstra test. Weight loss in the severe group (G2 + G3) was 3.4 (0.5-5.8) kg [A, n = 12] and 5.6 (4.4-9) kg [T, n = 43] [P = 0.026, Mann-Whitney U test]. The lengths of hospital stay were 5 (2-7), 9 (7-15), and 18 (12-26) days [P < 0.001, Jonckheere-Terpstra test]. In our fluid restriction management, patients with severe COVID-19 had significant longer hospital length of stay, weight loss, especially those who were transferred to the hospital.

摘要

液体管理与 2019 冠状病毒病(COVID-19)严重程度、治疗时间和结果之间的关系尚未完全阐明。本研究旨在评估住院期间体重变化与 COVID-19 严重程度、住院时间和入院途径的关系。在这项研究中,我们评估了限制液体摄入对严重 COVID-19 患者的效果。分析了 2020 年 7 月至 2021 年 10 月期间我院收治的 COVID-19 患者。患者根据日本指南接受标准药物治疗,并根据疾病严重程度给予呼吸支持。还给予早期肠内营养、排便管理和抗凝治疗。除非存在血流动力学不稳定或高乳酸血症,否则使用呋塞米和持续肾脏替代疗法进行液体限制管理。分析患者的背景、入院途径(救护车,A;转院,T)、入院和出院时的体重、疾病严重程度(氧疗,G1;机械通气,G2;体外膜氧合,G3)、院内死亡率和住院时间。共纳入 116 例患者:G1(n=48)、G2(n=43)和 G3(n=25),年龄(中位数[四分位数范围])分别为 58(47-70)、65(53-71.5)、56(51-62)岁,分别有 40(83.3%)、31(72.1%)和 19(76.0%)例男性。住院时间分别为 4.5(2-7)、10(7-16)和 18(15-26)天,院内死亡率分别为 0(0%)、7(16.3%)和 8(32%)。入院时的 BMI 分别为 26(23.1-30.2)、27.1(22.7-31.1)和 31.5(27.1-33.1)kg/m,住院期间体重减轻分别为 1.1(0-2.9)、4.6(2.3-5.7)和 9.2(5.6-10.5)kg(P<0.001,Jonckheere-Terpstra 检验)。重症组(G2+G3)体重减轻 3.4(0.5-5.8)kg[A,n=12]和 5.6(4.4-9)kg[T,n=43](P=0.026,Mann-Whitney U 检验)。住院时间分别为 5(2-7)、9(7-15)和 18(12-26)天[P<0.001,Jonckheere-Terpstra 检验]。在我们的液体限制管理中,严重 COVID-19 患者的住院时间明显延长,体重减轻,特别是那些转院的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验